USMLE Step1 SuperMemo KQB Pharmacology

Go back to the Database List

/KQB Pharmacology section.001-050
C: Pharmacology Q: The use of ..., a prokinetic agent, that stimulate GI tract, is absolutly containdicated in Pt with bowel obstuction. A: Metoclopramide 3: GI 4: Qbank 001-050.01

C: Pharmacology Q: ACE inhibitors are proven to delay progression of CHF by protecting the ventricles from ... A: remodeling 3: CardioVascular 4: Qbank 001-050.03

C: Pharmacology Q: Ammonium Cloride ... the urine increase toxicity with ..., used for threatment of metabolic ... and ... states A: -acidify urine//-salycilate//Rx:-metabolic alcalosis and hypoCl 3: Drug Interaction 4: Qbank 001-050.05

C: Pharmacology Q: Gradual return to conciusness with cessation of seizure activity is __ A: Tonic-Clonic seizures 3: Difference btw TonicClonic and Status Epilepticus 4: Qbank 001-050.14

C: Pharmacology Q: No return to conciusness and no cessation of seizure activity is __ A: Status Epilepticus (med emergency) 3: Difference btw TonicClonic and Status Epilepticus 4: Qbank 001-050.14

C: Pharmacology Q: Rx of Status Epilepticus, wich is medical emergency A: -Diazepam (benzo)//-Phenytoin for long term seizure control 3: Medical Emergency 4: Qbank 001-050.14

C: Pharmacology Q: Rx for Klebsiella Pneumonie is A: -Cefotaxime//-Ceftriaxone//-Ceftazidomide//(3rd generation of cefalosporin) 3: Rx for Pneumonia 4: Qbank 001-050.16

C: Pharmacology Q: Gentamicin used as addition to Vancomicin or Penicillin in the treatment of [2] A: -Pseudomonas//-Enterococcus 3: Rx for Pneumonia 4: Qbank 001-050.16

C: Pharmacology Q: Maximum effect that can be produced by a drug, regardless of dose is ... A: Efficacy 3: Terminology 4: Qbank 001-050.17

C: Pharmacology Q: The dose of concentration required to produce 50% of the drug maximum effect is ... A: Potency 3: Terminology 4: Qbank 001-050.17

C: Pharmacology Q: The dose that causes death in 50% of population is A: LD50 3: Terminology 4: Qbank 001-050.17

C: Pharmacology Q: NON Sulfa oral hypoglycemic agent for NIDDM Type 2 A: Metformin (biguanide) 3: Rx for Diabetis 4: Qbank 001-050.19

C: Pharmacology Q: HyperKalemia can be caused by ..., due to ... ... A: -Succinilcholine//-Prolonged depolarization 3: Misc 4: Qbank 001-050.21

C: Pharmacology Q: Coffeine inhibit ... => cAMP continius to activate ... => increase glycogen and triglyceride breakdown A: -Phoshodiesterase (PDE)//-Protein Kinase A 3: Mechanism of Action 4: Qbank 001-050.28

C: Pharmacology Q: ... decrease hepatic glucose output and improves perepheral insulin utilization A: Pioglitazone 3: Rx for Diabetis 4: Qbank 001-050.29

C: Pharmacology Q: ... can cause Lactic Acidosis A: Metformin (or nephrotoxic drugs) 3: Misc 4: Qbank 001-050.31

C: Pharmacology Q: Amoxapine is a ..., can cause ... ... syndrome A: -TCA//-Neuroleptic Malignan Syndrome 3: Misc 4: Qbank 001-050.33

C: Pharmacology Q: Severe idiosyncratic hepatocellular injury can follow ... administration. A: Troglitazone 3: Rx for Diabetis 4: Qbank 001-050.48

C: Pharmacology Q: Direct antispasmodic effect and inhibit the muscarinic action of Ach on smooth muscle, used in bladder instability (urinary urgency and incontinence) A: Oxybutynin 3: Misc 4: Qbank 001-050.49

C: Pharmacology Q: activation of ... ... receptor produce stronges Ca++ flux A: -Alpha.1 adrenergic receptor 3: Misc 4: Qbank 001-050.50

/KQB Pharmacology section.051-100
C: Pharmacology Q: ... - aPTT//activated Partial Tromboplasmin Time A: Heparin 3: Anticoagulants 4: Qbank 051-100.4

C: Pharmacology Q: Bleeding time - measure of ... A: Platelet fx 3: Anticoagulants 4: Qbank 051-100.4

C: Pharmacology Q: Internaional Normalized Ratio (INR) and //Protrombin Time (PT) used to monitor ... (...) A: coumarin (warfarin) 3: Anticoagulants 4: Qbank 051-100.4

C: Pharmacology Q: ... is a selective estrogen agonist and favorable effect on LDL and cholesterol A: Raloxifene 3: Endocrin 4: Qbank 051-100.5

C: Pharmacology Q: Tamoxifen is ... ... ... A: competitive estogen antagonist 3: Endocrin 4: Qbank 051-100.5

C: Pharmacology Q: Valproic acid DOC for ... syndrome, because it very effective and it is ... A: -myoclonic synd//-nonsedating 3: Seizures 4: Qbank 051-100.8

C: Pharmacology Q: Celecoxib ... drug ... inhibitor A: -sulfa//-COX2 3: Antiinflam 4: Qbank 051-100.9

C: Pharmacology Q: Ketorolac - ... A: NSAID 3: Antiinflam 4: Qbank 051-100.9

C: Pharmacology Q: Tramadol - ... ... stimulator (analgetic and resp depression) and inhibit uptake of ... and ... A: -mu opiate//-serotonin and NE 3: CNS 4: Qbank 051-100.9

C: Pharmacology Q: Metoclopramid is a ... agent indicated for the treatment of ... and ... ... A: -prokinetic//-GERD and diabetic gastroparesis 3: Misc 4: Qbank 051-100.10

C: Pharmacology Q: Metoclopramid antogonize ... receptors, leading to ... A: -dopamin//-Parkinson 3: Misc 4: Qbank 051-100.10

C: Pharmacology Q: Cisapride ... agent for the treatment of ..., associated with ... ... and ... ... A: -prokinetic//-GERD//-arrhythmias, diarrhea and abdominal cramping 3: Misc 4: Qbank 051-100.10

C: Pharmacology Q: Sucralfate - ... A: constipation 3: Adverse Effects 4: Qbank 051-100.10

C: Pharmacology Q: Meperidin narcotic with ... propertis (...), for ... A: -antimuscarinic (no spasm)//-gallstones 3: Misc 4: Qbank 051-100.11

C: Pharmacology Q: Obsessive-Compulsive Disorder threat with ... (...), ... (...) A: -TCA (clomipramine)//-SSRI (fluoxetine) 3: CNS 4: Qbank 051-100.12

C: Pharmacology Q: ... increase appetite A: Megistrol 3: Misc 4: Qbank 051-100.18

C: Pharmacology Q: Sustained eyes deviation is a form of dystonia called ... ... A: oculogyric crisis 3: CNS 4: Qbank 051-100.20

C: Pharmacology Q: oculogyric crisis after ... A: haloperidol 3: CNS 4: Qbank 051-100.20

C: Pharmacology Q: oculogyric crisis preventable with ... (...), ... (...), ... A: -antihystamines (diphenhydramine),//-antiholinergic (benzotropine),//-diazepam 3: CNS 4: Qbank 051-100.20

C: Pharmacology Q: ... - ... ... - feeling of restlessness, frequent stereotyped movement, inability to sit still. A: Akathisia - extrapyramidal synd 3: CNS 4: Qbank 051-100.20

C: Pharmacology Q: ... and ... save in pregnancy to treat HTN A: Methyldopa and Hydralazine 3: Misc 4: Qbank 051-100.21

C: Pharmacology Q: ... inhibit warfarin metabolism A: Norfloxacin 3: Misc 4: Qbank 051-100.23

C: Pharmacology Q: ... ... will treat arthralgias and skin rash in serum sickness A: Oral Prednisone 3: Misc 4: Qbank 051-100.24

C: Pharmacology Q: ... will treat urticaria in serum sickness A: Diphenhydramine 3: Misc 4: Qbank 051-100.24

C: Pharmacology Q: alpha_1 blocker ... good in BPH and HT A: Terazozin 3: Misc 4: Qbank 051-100.25

C: Pharmacology Q: Labetalol ... and ... ... ... indicated for ... A: -Alpha and Beta receptor Blocker//-HTN 3: Misc 4: Qbank 051-100.25

C: Pharmacology Q: Cocain ... ... ... A: bloking NE reuptake 3: Mechanism Of Action 4: Qbank 051-100.26

C: Pharmacology Q: Lidocaine, Mexiletine, Tocainide classified as class ... antiarrhythmic agents. ..., block ... channel and shorten ..., ... duration. A: -1B//-V-Tach//-Na//-AP, ERP 3: Misc 4: Qbank 051-100.27

C: Pharmacology Q: Estmolol is a class ..., with ultrashort acting ... ... and ... properties. A: -II//-Beta_1 blockage//-cardioselective 3: Misc 4: Qbank 051-100.27

C: Pharmacology Q: Diltiazem and Verapamil are ... channels blocker, and class ..., slow ... and ... conduction. A: -Ca++//-IV//-SA and AV 3: Misc 4: Qbank 051-100.27

C: Pharmacology Q: Disopyramide and Procainamide are class ... A: IA 3: Misc 4: Qbank 051-100.27

C: Pharmacology Q: Alcohol ... P450 in the ... of the liver.//Prove with elevated ... ... (...) A: -enchances P450 in the SER//-GammaGlutamyl Transferase (GGT) 3: Misc 4: Qbank 051-100.28

C: Pharmacology Q: 5FU in DNA synthesis substiture ...,//in RNA - ... A: DNA - THYMINE//RNA - Uracil 3: Misc 4: Qbank 051-100.29

C: Pharmacology Q: Clarithromycin ... hepatic enzymes => ... warfarin activity. A: -inhibit hepatic enzymes//-enhances warfarin activity 3: Misc 4: Qbank 051-100.30

C: Pharmacology Q: ... inhibits biogenic amines reuptake at the presynaptic neuron. A: TCA 3: CNS 4: Qbank 051-100.31

C: Pharmacology Q: Plasma concentration ...% = 1*t1/2 A: 50% 3: Misc 4: Qbank 051-100.32

C: Pharmacology Q: Plasma concentration ...% = 2*t1/2 A: 75% 3: Misc 4: Qbank 051-100.32

C: Pharmacology Q: Plasma concentration ...% = 3*t1/2 A: 87.5% 3: Misc 4: Qbank 051-100.32

C: Pharmacology Q: ... treat acne. A: Tetracycline 3: Misc 4: Qbank 051-100.34

C: Pharmacology Q: Tetracycline precipitate with ... drug. A: antiacid 3: Mics 4: Qbank 051-100.34

C: Pharmacology Q: Beta Blocker with intrinsic Sympat activity ... and ... are not indicated in ... A: -ACEBUTALOL and PINDOLOL//-angina 3: Misc 4: Qbank 051-100.35

C: Pharmacology Q: Amphetamines induces ... release (... ...) A: -DOPAMIN//-(indirect agonist) 3: CNS 4: Qbank 051-100.36

C: Pharmacology Q: Amphetamines induce ... ... wich lead to HTN (__) A: -NE release//-(no CNS effect) 3: CNS 4: Qbank 051-100.36

C: Pharmacology Q: Bleomycin, Hydroxyurea, Mercaptopurine, Vincristine level ... antyemetic agents. (__) A: -1//-(no emesis) 3: Misc 4: Qbank 051-100.37

C: Pharmacology Q: Pyridostigmine and Neostygmine inhibit AcetilCholineEsterase by ... A: Carbamylation 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: Edrophonium short acting ... inhibitor of AcetilCholineEsterase. A: competitive 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: Pralidoxime inhibit AcetilCholineEsterase by ... A: Dephosphorylation 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: Pilocarpin and Betanechol are ... ... agonists. A: direct muscarinic agonists 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: Curare ... ... blockers. A: direct Nicotinic blockers 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: Echothiophate (and nerve gases) inhibit AcetilCholineEsterase by ... A: Phosphorilation 3: Misc 4: Qbank 051-100.45

C: Pharmacology Q: ASA inhibit platelet aggregation by inhibiting production of ... A: Tromboxane A2 3: Anticoagulants 4: Qbank 051-100.48

/KQB Pharmacology section.101-150
C: Pharmacology Q: ... have active metabolites, phenobarbital and phenethylmalonamide (PEMA) A: Primidone 3: CNS 4: Qbank 101-150.01

C: Pharmacology Q: ... is a benzodiazapine used for the treatment of absence, mioclonic, atypical absence, Lennox-Gastaut seizures. A: Clonazepam 3: CNS 4: Qbank 101-150.01

C: Pharmacology Q: ... used for the treatment of partial seizures in adult and neuropathic pain in Diabetis A: Gabapentin 3: CNS 4: Qbank 101-150.01

C: Pharmacology Q: ... is antiepileptic agent used for the treatment and prevention of tonic-clonic, focal, psychomotor seizures. A: Phenytoin 3: CNS 4: Qbank 101-150.01

C: Pharmacology Q: amide-type local anasthetic (hepatic amidases) ... A: double-i 3: Anasthetics 4: Qbank 101-150.02

C: Pharmacology Q: ester-type local anasthetic (plasma cholinestherase and hepatic esterases) ... A: single-i 3: Anasthetics 4: Qbank 101-150.02

C: Pharmacology Q: interaction of ... containing food with MonoAmine Oxidase Inhibitors (MAOIs) A: thyramine 3: Drug Interaction 4: Qbank 101-150.03

C: Pharmacology Q: ... 5-HT3 receptor blockers - are antiemetic and antinauseant agents for cancer therapy A: *setron 3: CNS 4: Qbank 101-150.05

C: Pharmacology Q: ... a mix of ligand gated ion channel receptor and G-protein coupled receptor. Increase ... rate. A: -NMDA N-Methyl-D-Aspartat//-Firing 3: CNS 4: Qbank 101-150.06

C: Pharmacology Q: ... is a TriCyclic Antidepressant with significant ... effect. A: -Amitriptylin//-anticholinergic 3: CNS 4: Qbank 101-150.07

C: Pharmacology Q: ... potentiate the effect of GABA, which result in antianxiety effect. A: Benzodiazepines 3: CNS 4: Qbank 101-150.11

C: Pharmacology Q: Cardioselective B1 blockers ___ A: "A BEAM"//-Acebutalol,//-Betaxolol,//-Esmolol,//-Atenolol,//-Metoprolol. 3: Cardio 4: Qbank 101-150.13

C: Pharmacology Q: Labetolol blocks ..., ..., ...//Used in ... and .... A: -Alpha.1, Beta.1, Beta.2//-HTN and pheochromocytoma 3: Cardio 4: Qbank 101-150.13

C: Pharmacology Q: ... blocks Beta.1 Beta.2 with long t1/2 (14/24hrs). A: Nadolol 3: Cardio 4: Qbank 101-150.13

C: Pharmacology Q: Prazosin blocks ...//Used in .... A: -Alpha.1//-HTN 3: Cardio 4: Qbank 101-150.13

C: Pharmacology Q: ... blocks Beta.1 Beta.2 in open angle glaucoma. A: Timolol 3: Beta Blockers 4: Qbank 101-150.13

C: Pharmacology Q: ... atypical antidepressant with sedative side effect and priapism. A: Trazodon 3: CNS 4: Qbank 101-150.14

C: Pharmacology Q: ... decrease conduction through AV node A: Digoxin 3: Cardio 4: Qbank 101-150.15

C: Pharmacology Q: Ventricula tachycardia = ... ... complex A: wide QRS compex 3: Cardio 4: Qbank 101-150.16

C: Pharmacology Q: ... is a Type ... antiarrhythmic agent with ... ... node automaticity, Increase ... ... and Decrease ... nodal conduction velocity. A: -Propranolol//-Type II//-Decrease SA//-Increase AV ERP//-Decrease AV velocity 3: Beta Blocker 4: Qbank 101-150.16

C: Pharmacology Q: BENZO <- ... A: FLUMAZENIL 3: Detox 4: Qbank 101-150.23

C: Pharmacology Q: ... <- ACETOMINOPHEN (Tylenol) A: ACETYLCYSTEINE 3: Detox 4: Qbank 101-150.23

C: Pharmacology Q: Crohn's disease treat with ... (i.e. ...)//-... in Ulcerative colitis. A: -corticosteroid (i.e. prednizone)//-suppositories in Ulcerative colitis. 3: GI 4: Qbank 101-150.24

C: Pharmacology Q: ... have high risk of seizures, contrindicated in bulimia or anorexia nervosa. A: Bupropion 3: CNS 4: Qbank 101-150.25

C: Pharmacology Q: ... approved for anorexia nervosa and bulimia. A: Fluoxetine 3: CNS 4: Qbank 101-150.25

C: Pharmacology Q: Aspirin inhibit ... .... The result is a ... ... ... related to ... .... A: -secondary aggregation//-prolonged bleeding time//-platelet disFx 3: Coagulation 4: Qbank 101-150.29

C: Pharmacology Q: Indapamide, Metolazone are ... .... A: thiazide diuretics 3: Classification 4: Qbank 101-150.32

C: Pharmacology Q: Hallmark of CLL is isolated ... ... ..%-..%. A: -mature lymphocytosis//-75%-95% 3: Leukemia 4: Qbank 101-150.33

C: Pharmacology Q: Clorambucil, nitrogen mustard, ... ..., A: -alkalating DNA 3: Anticancer Drugs 4: Qbank 101-150.33

C: Pharmacology Q: Clorambucil used in ..., ... ... and ... A: -CLL//-Ovarian CA//-Hodgkin's 3: Anticancer Drugs 4: Qbank 101-150.33

C: Pharmacology Q: Sumatriptan may cause ... ... A: hypertensive crisis 3: CNS 4: Qbank 101-150.35

C: Pharmacology Q: Hypertensive emergency is elevated ... BP >...mmHg A: -diastolic//>130 mmHg 3: HTN 4: Qbank 101-150.35

C: Pharmacology Q: ... can cause Wolf Parkinson White synd. A: Digoxin 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: Wolf Parkinson White synd is a specific ... ... make ... ... btw the atria and ventricule through the ... .... A: -reentry tachycardia//-direct connection//-Kent bundels 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: Wolf Parkinson White synd produce ... ... interval, but an early delta wave at the onset of ... ... ... .... A: -short PR//-wide, slurred QRS complex 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: Examples of reentrant tachycardia are ... ..., ... (... ... ...), ... ..., mcc ... (... ... ... synd) A: -mcc WPWS (Wolf Parkinson White synd)//-atrial fib//-AVRT (AV reentrant tach)//-atrial flutter 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: ... is primarily used for conversion of paroxismal supraventricular tach, including WPWS to normal sinus rhythm. A: Adenosine 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: ... used in the treatment of refractory ventricular tach and supraventricular tach, and prevention of ventr tach/fib A: Amiodarone 3: Cardio 4: Qbank 101-150.40

C: Pharmacology Q: ... and ... are tetracyclines excreted by NONRENAL routes (intestinal lumen) A: -Doxycycline//-Minocycline 3: Antibiotics 4: Qbank 101-150.42

C: Pharmacology Q: intravenous infusion = ... dose A: maintenance 3: Pharmacokinetics 4: Qbank 101-150.46

C: Pharmacology Q: ... is a beta blocker can cause dyslipidemias in patiens. A: Metoprolol 3: Beta Blockers 4: Qbank 101-150.47

C: Pharmacology Q: Guanfacin a centrally acting ... receptor ... A: -alpha.2 agonist 3: CNS 4: Qbank 101-150.47

C: Pharmacology Q: Selegiline inhibit ... (... ... ...). Use in ... A: -MAO-B (which methabolise dopamine)//-Parkinson 3: CNS 4: Qbank 101-150.49

C: Pharmacology Q: MAO-A methabolise ... and ... A: -NE//-Serotonin 3: CNS 4: Qbank 101-150.49

C: Pharmacology Q: ... exacerbate CHF. A: Verapamil 3: Ca++ channel blockers 4: Qbank 101-150.50

/KQB Pharmacology section.151-164
C: Pharmacology Q: Loop diuretics works with Creatinin Clearence >... A: > 10 3: Pharmacokinetics 4: Qbank 151-164.04

C: Pharmacology Q: Thiazide and K_sparing works with Creatinin Clearence >... A: > 40 3: Pharmacokinetics 4: Qbank 151-164.04

C: Pharmacology Q: ACE inhibitor produce ..., mild ... A: -HyperKalemia//-mild HypoNatremia 3: ACE inhibitors 4: Qbank 151-164.07

C: Pharmacology Q: Digoxin + ... and ... (...) lead to Premature Ventricular Contraction A: hypoKalemia and hypoMagnesemic (diuretic) 3: Cardio 4: Qbank 151-164.08

C: Pharmacology Q: Doxepin is a ... with ... propertis (..., ... ...) A: -TCA//-antiholinergic//-(tachycardia, dry mouth) 3: CNS 4: Qbank 151-164.

C: Pharmacology Q: Propyothiouracil primarily inhibit ... ..., (inhibition of conversion ...->... in ...) A: -deiodination of thyroxine//-(inhibition of conversion T4->T3 in liver) 3: Anticancer drug 4: Qbank 151-164.12

C: Pharmacology Q: ... and ... => hemorrhagic cystitis <= prophilaxis with ... A: -Ifosfamid and Cyclophosphamide//-prophilaxis with MESNA 3: Anticancer drugs 4: Qbank 151-164.13